Collaborative drug therapy management gives pharmacists real prescriptive latitude — adjusting doses, ordering labs, initiating or discontinuing therapy — but every bit of that latitude runs through a written agreement and a documentation trail that has to hold up if a board or the collaborating physician’s practice ever gets audited. Loose documentation is the most common way a legitimate CDTM arrangement turns into a compliance problem.
CDTM vs. collaborative practice agreements
CDTM is often used interchangeably with “collaborative practice agreement” (CPA), and in many states they’re the same regulatory mechanism. Where states draw a distinction, CDTM typically refers specifically to protocols governing ongoing drug therapy adjustment — titrating a statin, adjusting an anticoagulant dose based on INR, managing a diabetes regimen — while CPA is sometimes used as the broader umbrella term covering any delegated collaborative function, including things like ordering certain lab tests or initiating preventive therapies. We cover the broader landscape in our post on collaborative practice agreements by state; this post focuses specifically on the drug therapy management piece and what boards expect documented.
What CDTM authorizes
Under a properly executed CDTM agreement, a pharmacist can typically:
- Initiate, modify, or discontinue drug therapy within the scope defined by the protocol
- Order and interpret relevant lab tests tied to the managed condition
- Adjust dosages based on lab results, clinical response, or defined parameters
- Substitute therapeutically equivalent medications within the agreement’s scope
What CDTM does not typically authorize is independent diagnosis or treatment outside the specific disease states and drug classes named in the agreement. The pharmacist is operating within a protocol a physician or physician group has approved and signed, not practicing independently — this is a delegated authority, not an autonomous one.
Where scope varies by state
Practitioner requirements. Most states require the collaborating physician (or in some states, other prescribers like NPs or PAs) to be actively practicing and to have a bona fide relationship with the patients covered under the agreement — not a rubber-stamp arrangement where a physician signs off on a broad protocol without ongoing clinical involvement.
Practice setting restrictions. Some states limit CDTM to specific settings — hospitals, health systems, or ambulatory care clinics — while others permit it in community pharmacy settings as well. If you’re hoping to run a CDTM-based clinical service out of a retail pharmacy, confirm your state actually permits that setting before building the program.
Disease state and drug class limitations. States differ on whether CDTM agreements can cover any condition the collaborating physician agrees to, or whether the state restricts CDTM to a defined list of chronic disease states (commonly diabetes, hypertension, anticoagulation, asthma, and dyslipidemia).
Registration or notification requirements. A number of states require the CDTM agreement itself — or at minimum notice that one exists — to be filed with or approved by the board of pharmacy before it takes effect. Practicing under an unregistered agreement in one of these states is a compliance gap even if the clinical content of the agreement is sound.
Documentation standards
This is where most CDTM compliance problems actually surface. Boards and collaborating practices generally expect:
The written agreement itself, specifying the scope of practice, the disease states or drug classes covered, the pharmacist’s specific authorized actions, and the review/renewal schedule for the agreement (commonly annual).
Contemporaneous clinical documentation for every action taken under the protocol — a dose adjustment made under CDTM needs the same clinical rationale documented as a prescriber would document, not just a note that a change was made.
Communication back to the collaborating practitioner, on a schedule the agreement specifies — this might be real-time for significant changes, or periodic summary reporting for routine titration. Undocumented or inconsistent communication back to the prescriber is one of the more common findings when these arrangements are reviewed.
Periodic agreement review and renewal, since most states require CDTM agreements to be reviewed and re-signed on a regular cycle rather than standing indefinitely.
How CDTM fits with broader prescriptive authority
CDTM is one piece of a broader expansion of pharmacist clinical authority that also includes independent prescribing for certain conditions, test-and-treat protocols, and point-of-care testing authority in some states. If you’re building a clinical practice, it’s worth understanding how these overlap — see our posts on expanding pharmacist prescriptive authority, test-and-treat authority by state, and point-of-care testing authority. Liability exposure also increases with clinical scope, so make sure your coverage matches what you’re actually doing — our malpractice insurance requirements guide is a useful cross-check.
The bottom line
CDTM gives pharmacists meaningful clinical latitude, but that latitude is only as defensible as the paper trail behind it. Before entering into or expanding a CDTM arrangement, confirm your state’s specific scope limitations, any board filing or registration requirement, and the documentation standard expected — these vary enough between states that a CDTM practice built around one state’s rules may not transfer cleanly if you relocate or add a license elsewhere.
RxByState tracks collaborative practice and prescriptive authority rules across all 50 states, so you always know what a CDTM agreement can and can’t authorize wherever you practice. Start a free 14-day trial →